Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China
· Delayed Price · Currency is CNY 54.89
+0.05 (0.09%)
Apr 29, 2026, 2:05 PM CST
SHA:600276 Revenue
Jiangsu Hengrui Pharmaceuticals Co.,Ltd had revenue of 8.14B CNY in the quarter ending March 31, 2026, with 12.98% growth. This brings the company's revenue in the last twelve months to 32.56B, up 11.55% year-over-year. In the year 2025, Jiangsu Hengrui Pharmaceuticals Co.,Ltd had annual revenue of 31.63B with 13.02% growth.
Revenue (ttm)
32.56B
Revenue Growth
+11.55%
P/S Ratio
11.17
Revenue / Employee
1.58M
Employees
20,602
Market Cap
363.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.63B | 3.64B | 13.02% |
| Dec 31, 2024 | 27.98B | 5.16B | 22.63% |
| Dec 31, 2023 | 22.82B | 1.54B | 7.26% |
| Dec 31, 2022 | 21.28B | -4.63B | -17.87% |
| Dec 31, 2021 | 25.91B | -1.83B | -6.59% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sichuan Biokin Pharmaceutical | 2.52B |
| Zhejiang NHU Company | 22.25B |
| Yunnan Baiyao Group Co.,Ltd | 41.19B |
| Shanghai Fosun Pharmaceutical (Group) | 41.66B |
| Shenzhen Salubris Pharmaceuticals | 4.52B |
| Huadong Medicine | 44.06B |
| China Resources Sanjiu Medical & Pharmaceutical | 32.88B |
| Beijing Tongrentang | 17.26B |
Jiangsu Hengrui Pharmaceuticals Co.,Ltd News
- 15 hours ago - Nuobikan Back To Earth After Spectacular Debut - Benzinga
- 5 days ago - Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy - Benzinga